| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A gap analysis of opportunities and priorities for breast surgical research
|
Gentilini, Oreste D
|
|
2019
|
20 |
1 |
p. e1
|
artikel
|
| 2 |
2018 American Society of Hematology Annual Meeting
|
Gourd, Katherine
|
|
2019
|
20 |
1 |
p. 26
|
artikel
|
| 3 |
Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration
|
Riedel, Richard F
|
|
2019
|
20 |
1 |
p. 14-15
|
artikel
|
| 4 |
Catching up on medical device safety
|
The Lancet Oncology,
|
|
2019
|
20 |
1 |
p. 1
|
artikel
|
| 5 |
CD19-directed CAR T cells gain traction
|
Schuster, Stephen J
|
|
2019
|
20 |
1 |
p. 2-3
|
artikel
|
| 6 |
Childhood cancer burden: a review of global estimates
|
Bhakta, Nickhill
|
|
2019
|
20 |
1 |
p. e42-e53
|
artikel
|
| 7 |
Competing risks of extended adjuvant aromatase inhibitors
|
Amir, Eitan
|
|
2019
|
20 |
1 |
p. 8-9
|
artikel
|
| 8 |
Correction to Lancet Oncol 2018; 19: 1493–503
|
|
|
2019
|
20 |
1 |
p. e9
|
artikel
|
| 9 |
Correction to Lancet Oncol 2018; 19: 1569–78
|
|
|
2019
|
20 |
1 |
p. e10
|
artikel
|
| 10 |
Correction to Lancet Oncol 2018; 19: 1680–87
|
|
|
2019
|
20 |
1 |
p. e10
|
artikel
|
| 11 |
Correction to Lancet Oncol 2018; 19: 1654–67
|
|
|
2019
|
20 |
1 |
p. e10
|
artikel
|
| 12 |
Correction to Lancet Oncol 2019; 20: 88–99
|
|
|
2019
|
20 |
1 |
p. e10
|
artikel
|
| 13 |
Correction to Lancet Oncol 2018; 19: 1590–601
|
|
|
2019
|
20 |
1 |
p. e10
|
artikel
|
| 14 |
Correction to Lancet Oncol 2017; 18: 672–81
|
|
|
2019
|
20 |
1 |
p. e9
|
artikel
|
| 15 |
Correction to Lancet Oncol 2019; 20: 43–56
|
|
|
2019
|
20 |
1 |
p. e10
|
artikel
|
| 16 |
Derazantinib for intrahepatic cholangiocarcinoma
|
Gourd, Elizabeth
|
|
2019
|
20 |
1 |
p. e11
|
artikel
|
| 17 |
Digitally enabled patient-reported outcome measures in cancer care
|
Lindner, Oana C
|
|
2019
|
20 |
1 |
p. e2
|
artikel
|
| 18 |
Digitally enabled patient-reported outcome measures in cancer care – Authors' reply
|
Heathcote, Lauren C
|
|
2019
|
20 |
1 |
p. e3
|
artikel
|
| 19 |
Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma?
|
Adams, Hugo J A
|
|
2019
|
20 |
1 |
p. e4
|
artikel
|
| 20 |
Does end-of-treatment FDG-PET improve outcomes in follicular lymphoma? – Authors' reply
|
Trotman, Judith
|
|
2019
|
20 |
1 |
p. e5
|
artikel
|
| 21 |
Drug development for glioma: are we repeating the same mistakes?
|
Stupp, Roger
|
|
2019
|
20 |
1 |
p. 10-12
|
artikel
|
| 22 |
Dying to survive and cancer care in China
|
Lucas, Catherine
|
|
2019
|
20 |
1 |
p. 30
|
artikel
|
| 23 |
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
|
Duffaud, Florence
|
|
2019
|
20 |
1 |
p. 120-133
|
artikel
|
| 24 |
Exclusive MRI-targeted biopsy: not so fast
|
Jayadevan, Rajiv
|
|
2019
|
20 |
1 |
p. 9-10
|
artikel
|
| 25 |
Exploring and comparing adverse events between PARP inhibitors
|
LaFargue, Christopher J
|
|
2019
|
20 |
1 |
p. e15-e28
|
artikel
|
| 26 |
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
|
Moreno, Carol
|
|
2019
|
20 |
1 |
p. 43-56
|
artikel
|
| 27 |
Ibrutinib: searching for a partner drug
|
Kater, Arnon P
|
|
2019
|
20 |
1 |
p. 3-5
|
artikel
|
| 28 |
Increasing access to next-generation sequencing in oncology for Brazil
|
Santos, Marcos
|
|
2019
|
20 |
1 |
p. 20-23
|
artikel
|
| 29 |
Intraoperative lymph-node assessment during NSCLC surgery: the need for standardisation and quality evaluation
|
Thomas, Pascal-Alexandre
|
|
2019
|
20 |
1 |
p. 23-25
|
artikel
|
| 30 |
Lenalidomide as maintenance for every newly diagnosed patient with multiple myeloma
|
Mateos, María-Victoria
|
|
2019
|
20 |
1 |
p. 5-6
|
artikel
|
| 31 |
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
|
Jackson, Graham H
|
|
2019
|
20 |
1 |
p. 57-73
|
artikel
|
| 32 |
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|
Locke, Frederick L
|
|
2019
|
20 |
1 |
p. 31-42
|
artikel
|
| 33 |
Metastatic osteosarcoma challenged by regorafenib
|
Heymann, Dominique
|
|
2019
|
20 |
1 |
p. 12-14
|
artikel
|
| 34 |
New directions in penile cancer
|
Johnstone, Peter A S
|
|
2019
|
20 |
1 |
p. 16-17
|
artikel
|
| 35 |
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
|
Martins, Filipe
|
|
2019
|
20 |
1 |
p. e54-e64
|
artikel
|
| 36 |
Oncology meets Art: a way to understand patients' symptoms
|
Bernard, Florian
|
|
2019
|
20 |
1 |
p. 27
|
artikel
|
| 37 |
One-view breast tomosynthesis vs two-view mammography: a methodological issue
|
Fang, Xiang
|
|
2019
|
20 |
1 |
p. e6
|
artikel
|
| 38 |
One-view breast tomosynthesis vs two-view mammography: a methodological issue – Authors' reply
|
Zackrisson, Sophia
|
|
2019
|
20 |
1 |
p. e7
|
artikel
|
| 39 |
Patient-reported outcome monitoring in a routine paediatric oncology setting: challenges and opportunities
|
Kaur, Geetinder
|
|
2019
|
20 |
1 |
p. 19-20
|
artikel
|
| 40 |
Patients' crowdfunding campaigns for alternative cancer treatments
|
Snyder, Jeremy
|
|
2019
|
20 |
1 |
p. 28-29
|
artikel
|
| 41 |
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial
|
Martin-Broto, Javier
|
|
2019
|
20 |
1 |
p. 134-144
|
artikel
|
| 42 |
Pregabalin alleviates radiotherapy-related neuropathic pain
|
Gourd, Elizabeth
|
|
2019
|
20 |
1 |
p. e12
|
artikel
|
| 43 |
Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis
|
Olesen, Tina Bech
|
|
2019
|
20 |
1 |
p. 145-158
|
artikel
|
| 44 |
Probiotics for chemoradiotherapy-induced oral mucositis
|
Das, Manjulika
|
|
2019
|
20 |
1 |
p. e14
|
artikel
|
| 45 |
Radiosurgery and risk of intracranial malignancies: more research needed
|
Berlin, Alejandro
|
|
2019
|
20 |
1 |
p. 17-18
|
artikel
|
| 46 |
Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium
|
Clemens, Eva
|
|
2019
|
20 |
1 |
p. e29-e41
|
artikel
|
| 47 |
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
|
Lombardi, Giuseppe
|
|
2019
|
20 |
1 |
p. 110-119
|
artikel
|
| 48 |
Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: a retrospective, multicentre, cohort study
|
Wolf, Amparo
|
|
2019
|
20 |
1 |
p. 159-164
|
artikel
|
| 49 |
Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study
|
Benitez Majano, Sara
|
|
2019
|
20 |
1 |
p. 74-87
|
artikel
|
| 50 |
T-DM1 for residual, invasive, HER2-positive breast cancer
|
Burki, Talha Khan
|
|
2019
|
20 |
1 |
p. e13
|
artikel
|
| 51 |
The importance of surgery in colorectal cancer treatment
|
Angenete, Eva
|
|
2019
|
20 |
1 |
p. 6-7
|
artikel
|
| 52 |
Trifluridine/tipiracil in metastatic gastric cancer
|
McCaw, Zachary R
|
|
2019
|
20 |
1 |
p. e8
|
artikel
|
| 53 |
Tyrosine kinase inhibitor-induced corneal ulcers
|
Kam, Ka Wai
|
|
2019
|
20 |
1 |
p. e65
|
artikel
|
| 54 |
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Mamounas, Eleftherios P
|
|
2019
|
20 |
1 |
p. 88-99
|
artikel
|
| 55 |
Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study
|
Rouvière, Olivier
|
|
2019
|
20 |
1 |
p. 100-109
|
artikel
|
Tijdschrift beschrijving